Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism
Metrics: PDF 1446 views | HTML 1968 views | ?
Zuzana Rychtarcikova1,2,*, Sandra Lettlova1,3,*, Veronika Tomkova1,3, Vlasta Korenkova1, Lucie Langerova1, Ekaterina Simonova1, Polina Zjablovskaja4, Meritxell Alberich-Jorda4, Jiri Neuzil1,5, Jaroslav Truksa1
1Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic
2Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, Czech Republic
3Charles University in Prague, Faculty of Sciences, Prague, Czech Republic
4Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic
5School of Medical Science, Menzies Health Institute Queensland, Southport, Queensland, Australia
*These authors contributed equally to this work
Jaroslav Truksa, email: firstname.lastname@example.org
Keywords: tumor-initiating cells, breast cancer, iron metabolism, FeS cluster, stem cells
Received: January 12, 2016 Accepted: November 30, 2016 Published: December 22, 2016
The importance of iron in the growth and progression of tumors has been widely documented. In this report, we show that tumor-initiating cells (TICs), represented by spheres derived from the MCF7 cell line, exhibit higher intracellular labile iron pool, mitochondrial iron accumulation and are more susceptible to iron chelation. TICs also show activation of the IRP/IRE system, leading to higher iron uptake and decrease in iron storage, suggesting that level of properly assembled cytosolic iron-sulfur clusters (FeS) is reduced. This finding is confirmed by lower enzymatic activity of aconitase and FeS cluster biogenesis enzymes, as well as lower levels of reduced glutathione, implying reduced FeS clusters synthesis/utilization in TICs. Importantly, we have identified specific gene signature related to iron metabolism consisting of genes regulating iron uptake, mitochondrial FeS cluster biogenesis and hypoxic response (ABCB10, ACO1, CYBRD1, EPAS1, GLRX5, HEPH, HFE, IREB2, QSOX1 and TFRC). Principal component analysis based on this signature is able to distinguish TICs from cancer cells in vitro and also Leukemia-initiating cells (LICs) from non-LICs in the mouse model of acute promyelocytic leukemia (APL). Majority of the described changes were also recapitulated in an alternative model represented by MCF7 cells resistant to tamoxifen (TAMR) that exhibit features of TICs. Our findings point to the critical importance of redox balance and iron metabolism-related genes and proteins in the context of cancer and TICs that could be potentially used for cancer diagnostics or therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.